Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914196 | 0.92 | P2RY12 (0.79) | P2RY12MEN1 | |
| SCHEMBL4921875 | 0.91 | P2RY12 (0.81) | P2RY12MEN1 | |
| SCHEMBL4921883 | 0.91 | P2RY12 (0.81) | P2RY12MEN1 | |
| SCHEMBL4918110 | 0.91 | P2RY12 (0.79) | P2RY12MEN1 | |
| SCHEMBL4919919 | 0.91 | P2RY12 (0.79) | P2RY12MEN1 | |
| SCHEMBL4914475 | 0.90 | P2RY12 (0.73) | P2RY12MEN1 | |
| SCHEMBL4914977 | 0.90 | P2RY12 (0.60) | P2RY12MEN1 | |
| SCHEMBL14113070 | 0.89 | P2RY12 (0.73) | P2RY12MEN1 | |
| SCHEMBL5312178 | 0.89 | P2RY12 (0.83) | P2RY12 | |
| SCHEMBL4910991 | 0.89 | P2RY12 (0.73) | P2RY12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | P2RY12 24/4885MEN1 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.